50 311

Cited 3 times in

Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology.

Authors
Chung, YR; Lee, K; Cho, EH; Lew, HM
Citation
Eye (London, England), 24(8):1320-1324, 2010
Journal Title
Eye (London, England)
ISSN
0950-222X1476-5454
Abstract
PURPOSE: We evaluated the effects of intravitreal injection of bevacizumab (Avastin; Novartis, Basel, Switzerland) on blood pressure (BP) in the context of ocular vascular pathology.



METHODS: This study retrospectively examined 135 consecutive patients treated with intravitreal injections of 1.25 mg bevacizumab for retinal vascular disease; there were 61 cases of diabetic retinopathy, 30 of retinal vein occlusion, 35 of choroidal neo-vascularization (CNV), and 9 of other retinal vascular diseases. BP was measured before injection and at 30 min, 1 day, 1 week, 3 weeks, and thereafter monthly over a 6-month period.



RESULTS: In the CNV group, 30-min post-injection systolic values were significantly higher than baseline, and systolic and diastolic values after 1 day, 1 week, and 3 weeks were significantly lower than before injection. No other pressure measurement differed significantly from baseline values in the other groups.



DISCUSSION: Intravitreal bevacizumab injection is safe in terms of its effect on BP, regardless of ocular pathology.
MeSH terms
AdultAgedAged, 80 and overAnalysis of VarianceAngiogenesis Inhibitors/*pharmacology/therapeutic useAntibodies, Monoclonal/*pharmacology/therapeutic useBlood Pressure/*drug effects/physiologyFemaleHumansIntravitreal InjectionsMaleMiddle AgedRetinal Diseases/drug therapyRetrospective Studies
DOI
10.1038/eye.2010.22
PMID
20379211
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Ophthalmology
AJOU Authors
정, 유리유, 호민
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse